16.44

2.24% 0.36

Pre-market: 16.52 0.08 +0.49%

Adaptive Biotechnologies Corp (ADPT)

Overview News Price History Option Chain Financials Why ADPT Down? Discussions Forecast

Adaptive Biotechnologies Corp stock is traded at $16.44, with a volume of 1.33M. It is up +2.24% in the last 24 hours and down -4.97% over the past month. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Previous Close:

$16.08

Open:

$16.15

24h Volume:

1.33M

Relative Volume:

0.63

Market Cap:

$2.53B

Revenue:

$205.22M

Net Income/Loss:

$-121.24M

P/E Ratio:

-20.19

EPS:

-0.8141

Net Cash Flow:

$-82.81M

1W Performance:

+1.42%

1M Performance:

-4.97%

6M Performance:

+26.27%

1Y Performance:

+102.46%

1-Day Range:

$16.15

$16.95

1-Week Range:

$15.11

$16.95

52-Week Range:

$6.255

$20.76

Adaptive Biotechnologies Corp Stock (ADPT) Company Profile

Name

Adaptive Biotechnologies Corp

Sector

Healthcare (1106)

Industry

Biotechnology (621)

Phone

206-659-0067

Address

1165 EASTLAKE AVE E, SEATTLE, WA

Employee

619

Twitter

@adaptivebiotech

Next Earnings Date

2025-02-11

Latest SEC Filings

ADPT's Discussions on Twitter

Compare ADPT vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADPT Adaptive Biotechnologies Corp	16.44	2.47B	205.22M	-121.24M	-82.81M	-0.8141
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-02-25	Resumed	Morgan Stanley	Equal-Weight
Sep-30-25	Initiated	Guggenheim	Buy
Jun-18-25	Initiated	Craig Hallum	Buy
Mar-21-25	Upgrade	Goldman	Neutral → Buy
Jul-05-23	Resumed	JP Morgan	Overweight
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Dec-21-22	Upgrade	Piper Sandler	Neutral → Overweight
Aug-25-22	Initiated	Credit Suisse	Underperform
Jun-03-22	Initiated	Piper Sandler	Neutral
Feb-16-22	Reiterated	BTIG Research	Buy
Feb-16-22	Reiterated	BofA Securities	Buy
Feb-16-22	Reiterated	Goldman	Neutral
Feb-16-22	Reiterated	JP Morgan	Overweight
Oct-15-21	Resumed	Cowen	Outperform
Mar-03-21	Downgrade	Goldman	Buy → Neutral
Oct-08-20	Resumed	BTIG Research	Buy
Sep-09-20	Initiated	Morgan Stanley	Equal-Weight
Jun-03-20	Initiated	Goldman	Buy
Jul-23-19	Initiated	BTIG Research	Buy
Jul-22-19	Initiated	BofA/Merrill	Buy
Jul-22-19	Initiated	Cowen	Outperform
Jul-22-19	Initiated	Goldman	Neutral
Jul-22-19	Initiated	Guggenheim	Buy
Jul-22-19	Initiated	William Blair	Outperform

View All

Adaptive Biotechnologies Corp Stock (ADPT) Latest News

04:00 AM

Amova Asset Management Americas Inc. Decreases Stake in Adaptive Biotechnologies Corporation $ADPT - MarketBeat

04:00 AM

Mar 04, 2026

Insider Sell: Harlan Robins Sells 24,233 Shares of Adaptive Biotechnologies Corp (ADPT) - GuruFocus

Mar 04, 2026

Adaptive Biotechnologies (NASDAQ:ADPT) Insider Harlan Robins Sells 10,000 Shares - MarketBeat

Mar 04, 2026

Adaptive Biotechnologies CSO Robins sells $392,329 in ADPT stock - Investing.com Australia

Mar 04, 2026

Mar 03, 2026

Chad Robins Sells 289,024 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock - MarketBeat

Mar 03, 2026

Adaptive Biotechnologies (NASDAQ:ADPT) CEO Sells $823,848.16 in Stock - MarketBeat

Mar 03, 2026

Insider Sell: Chad Robins Sells 524,998 Shares of Adaptive Biote - GuruFocus

Mar 03, 2026

CEO of Adaptive Biotechnologies (NASDAQ: ADPT) sells 524,998 shares - Stock Titan

Mar 03, 2026

Adaptive Biotechnologies CEO Sells Over $8 Million in Company Stock - TradingView

Mar 03, 2026

A Look At Adaptive Biotechnologies (ADPT) Valuation As CEO Updates MRD Growth And Profitability Outlook - simplywall.st

Mar 03, 2026